rs876660754
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |
rs1131691022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a proof of concept, we show that the combination of D269H/E195R, nutlin-3 and cisplatin induced massive apoptosis in ex vivo tissue slices of primary human ovarian cancers.
|
24136147 |
2013 |
rs1321845532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a proof of concept, we show that the combination of D269H/E195R, nutlin-3 and cisplatin induced massive apoptosis in ex vivo tissue slices of primary human ovarian cancers.
|
24136147 |
2013 |
rs2287497
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |
rs2287498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |
rs121913343
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
rs397516436
|
|
|
0.010 |
GeneticVariation |
BEFREE |
High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.
|
9579562 |
1998 |
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rs1042522 polymorphism was not overall associated with o</span>varian cancer risk.
|
25060098 |
2014 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |